HRP20020701B1 - A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR - Google Patents

A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Info

Publication number: HRP20020701B1
Authority: HR; Croatia
Prior art keywords: crystalline form; pyrrolo; pyrimidin; dihydro; benzoyl
Prior art date: 2000-02-25

Application number

HR20020701A

Other languages

English (en)

Croatian (hr)

Inventor

Christopher Chelius Erik

Marie Reutzel-Edens Susan

Van Den Berghe Snorek Sharon

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-25

Filing date

2001-02-12

Publication date

2011-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-02-12 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2003-12-31 Publication of HRP20020701A2 publication Critical patent/HRP20020701A2/hr

2011-02-28 Publication of HRP20020701B1 publication Critical patent/HRP20020701B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

HR20020701A 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR HRP20020701B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18496400P	2000-02-25	2000-02-25
PCT/US2001/001229 WO2001062760A2 (en)	2000-02-25	2001-02-12	A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (2)

Publication Number	Publication Date
HRP20020701A2 HRP20020701A2 (en)	2003-12-31
HRP20020701B1 true HRP20020701B1 (en)	2011-02-28

Family

ID=22679017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20020701A HRP20020701B1 (en)	2000-02-25	2001-02-12	A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Country Status (35)

Country	Link
US (1)	US7138521B2 (es)
EP (1)	EP1259513B1 (es)
JP (1)	JP4846158B2 (es)
KR (1)	KR100744917B1 (es)
CN (1)	CN1183135C (es)
AR (1)	AR029471A1 (es)
AT (1)	ATE249462T1 (es)
AU (1)	AU777047B2 (es)
BR (1)	BR0108604A (es)
CA (1)	CA2400155C (es)
CO (1)	CO5261585A1 (es)
CZ (1)	CZ303772B6 (es)
DE (1)	DE60100750T2 (es)
DK (1)	DK1259513T3 (es)
DZ (1)	DZ3283A1 (es)
EA (1)	EA004684B1 (es)
EG (1)	EG24073A (es)
ES (1)	ES2206403T3 (es)
HR (1)	HRP20020701B1 (es)
HU (1)	HU229704B1 (es)
IL (2)	IL150480A0 (es)
MX (1)	MXPA02008242A (es)
MY (1)	MY124784A (es)
NO (1)	NO323422B1 (es)
NZ (1)	NZ519796A (es)
PE (1)	PE20011082A1 (es)
PL (1)	PL208061B1 (es)
PT (1)	PT1259513E (es)
SI (1)	SI1259513T1 (es)
SK (1)	SK287375B6 (es)
SV (1)	SV2002000321A (es)
TW (1)	TWI237024B (es)
UA (1)	UA72791C2 (es)
WO (1)	WO2001062760A2 (es)
ZA (1)	ZA200205265B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100364993C (zh) *	2003-05-30	2008-01-30	江苏恒瑞医药股份有限公司	培美曲噻盐及其制备方法
CN100364994C (zh) *	2004-11-25	2008-01-30	重庆医药工业研究院有限责任公司	培美曲塞二钠的一种新晶型及其制备方法
AU2006311820A1 (en) *	2005-11-04	2007-05-18	Merck Sharp & Dohme Corp.	Methods of using SAHA and erlotinib for treating cancer
AU2006311808A1 (en) *	2005-11-04	2007-05-18	Merck Sharp & Dohme Corp.	Methods of using SAHA and bortezomib for treating cancer
EP1957497B1 (en)	2006-08-14	2015-09-30	Sicor, Inc.	Processes for preparing intermediates of pemetrexed
EP2305681A1 (en) *	2006-08-14	2011-04-06	Sicor, Inc.	Crystalline form of pemetrexed diacid and process for the preparation thereof
EP1934226A2 (en)	2006-08-14	2008-06-25	Sicor, Inc.	Highly pure pemetrexed diacid and processes for the preparation thereof
WO2008021411A2 (en) *	2006-08-14	2008-02-21	Sicor Inc.	Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
AU2007317921A1 (en) *	2006-11-03	2008-05-15	University Of Maryland, Baltimore	Methods of using SAHA and Bortezomib for treating multiple myeloma
KR20100014854A (ko)	2007-04-03	2010-02-11	닥터 레디스 레보러터리즈 리미티드	페메트렉세드의 고체 형태
CN101417998B (zh) *	2007-10-24	2012-10-24	重庆医药工业研究院有限责任公司	一种培美曲塞盐的纯化方法
EP2072518A1 (en)	2007-12-23	2009-06-24	Sun Pharma Advanced Research Company Limited	Stable Amorphous Form of Pemextred Disodium
EP2334685A4 (en) *	2008-09-08	2011-10-26	Reddys Lab Ltd Dr	AMORPHOUS PEMETREXED DISODIUM
WO2010030598A2 (en) *	2008-09-11	2010-03-18	Dr. Reddy's Laboratories Limited	Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh)	2008-09-22	2013-04-03	重庆医药工业研究院有限责任公司	培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) *	2009-11-05	2014-12-17	上海创诺制药有限公司	制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en)	2009-11-24	2015-11-03	Azad Pharmaceutical Ingredients Ag	Crystalline form of pemetrexed disodium
CN102372719B (zh) *	2010-08-26	2013-10-30	齐鲁制药有限公司	培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) *	2011-03-10	2011-09-30	건일제약 주식회사	페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en)	2011-03-23	2015-06-09	Scinopharm Taiwan, Ltd.	Process for the production of a pemetrexed salt
EP2688888B1 (en) *	2011-03-25	2017-06-14	Scinopharm Taiwan, Ltd.	Process for the production of disodium pemetrexed
ITRM20120398A1 (it)	2012-08-08	2014-02-09	Berlin Chemie Ag	Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) *	2012-10-10	2015-07-22	德州德药制药有限公司	一种培美曲塞二钠的制备方法
WO2014060959A1 (en) *	2012-10-17	2014-04-24	Shilpa Medicare Limited	Crystalline pemetrexed dipotassium process
ZA201400898B (en)	2013-02-06	2015-12-23	Cipla Ltd	Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
US20160051679A1 (en)	2013-04-12	2016-02-25	Actavis Group Ptc Ehf.	Pemetrexed Formulation
KR101485243B1 (ko)	2013-05-08	2015-01-21	씨제이헬스케어 주식회사	안정화된 페메트렉시드 제제
JP6094388B2 (ja) *	2013-06-07	2017-03-15	ニプロ株式会社	ペメトレキセドを含む注射用組成物
EP3008064B1 (en)	2013-06-14	2017-11-22	Synthon B.V.	Stable pemetrexed arginine salt and compositions comprising it
US9688682B2 (en)	2013-07-16	2017-06-27	Dr. Reddy's Laboratories Limited	Crystalline forms of pemetrexed tromethamine salts
PL3040074T3 (pl)	2013-10-03	2019-03-29	Fujifilm Corporation	Preparat iniekcyjny i sposób jego wytwarzania
NZ630292A (en) *	2013-11-25	2015-02-27	Shilpa Medicare Ltd	Process for crystalline pemetrexed dipotassium salt
NZ630299A (en)	2014-06-30	2014-11-28	Shilpa Medicare Ltd	Pemetrexed dipotassium formulations
EP3212193A4 (en) *	2014-10-30	2018-08-01	ScinoPharm Taiwan, Ltd.	Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) *	2014-11-06	2018-04-24	博瑞生物医药（苏州）股份有限公司	培美曲塞二酸多晶型的制备方法
PL3470045T3 (pl) *	2017-10-10	2021-03-08	Sun Pharmaceutical Industries Ltd	Dożylna infuzyjna postać dawkowania dla pemetreksedu
EP3749311A4 (en)	2018-02-07	2022-07-06	L.E.A.F Holdings Group LLC	PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
US11779584B2 (en)	2018-02-07	2023-10-10	L.E.A.F. Holdings Group Llc	Alpha polyglutamated pemetrexed and uses thereof
WO2025244944A1 (en) *	2024-05-20	2025-11-27	Opna Bio SA	Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO169490C (no)	1988-03-24	1992-07-01	Takeda Chemical Industries Ltd	Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko)	1989-12-11	1998-11-16	알렌 제이. 시니스갤리	N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en)	1992-09-25	1995-05-16	Eli Lilly And Company	Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (en) *	1996-08-30	1998-03-05	Eli Lilly And Company	Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
IL135190A (en) *	1997-09-26	2005-03-20	Lilly Co Eli	Processes and intermediates useful to make antifolates
ZA987550B (en) *	1997-09-26	2000-02-21	Lilly Co Eli	Processes and intermediates useful to make antifolates.
WO2001014379A2 (en) *	1999-08-23	2001-03-01	Eli Lilly And Company	A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

2001
- 2001-02-12 EP EP01906554A patent/EP1259513B1/en not_active Expired - Lifetime
- 2001-02-12 SI SI200130032T patent/SI1259513T1/xx unknown
- 2001-02-12 BR BR0108604-9A patent/BR0108604A/pt not_active Application Discontinuation
- 2001-02-12 DZ DZ013283A patent/DZ3283A1/fr active
- 2001-02-12 WO PCT/US2001/001229 patent/WO2001062760A2/en not_active Ceased
- 2001-02-12 PL PL356423A patent/PL208061B1/pl unknown
- 2001-02-12 SK SK1186-2002A patent/SK287375B6/sk not_active IP Right Cessation
- 2001-02-12 AU AU34451/01A patent/AU777047B2/en not_active Ceased
- 2001-02-12 DK DK01906554T patent/DK1259513T3/da active
- 2001-02-12 DE DE60100750T patent/DE60100750T2/de not_active Expired - Lifetime
- 2001-02-12 US US10/182,991 patent/US7138521B2/en not_active Expired - Lifetime
- 2001-02-12 CZ CZ20022875A patent/CZ303772B6/cs not_active IP Right Cessation
- 2001-02-12 NZ NZ519796A patent/NZ519796A/xx not_active IP Right Cessation
- 2001-02-12 AT AT01906554T patent/ATE249462T1/de active
- 2001-02-12 CN CNB01805627XA patent/CN1183135C/zh not_active Expired - Fee Related
- 2001-02-12 HU HU0204232A patent/HU229704B1/hu unknown
- 2001-02-12 JP JP2001562542A patent/JP4846158B2/ja not_active Expired - Fee Related
- 2001-02-12 HR HR20020701A patent/HRP20020701B1/xx not_active IP Right Cessation
- 2001-02-12 PT PT01906554T patent/PT1259513E/pt unknown
- 2001-02-12 ES ES01906554T patent/ES2206403T3/es not_active Expired - Lifetime
- 2001-02-12 KR KR1020027011122A patent/KR100744917B1/ko not_active Expired - Fee Related
- 2001-02-12 CA CA002400155A patent/CA2400155C/en not_active Expired - Fee Related
- 2001-02-12 MX MXPA02008242A patent/MXPA02008242A/es active IP Right Grant
- 2001-02-12 EA EA200200905A patent/EA004684B1/ru not_active IP Right Cessation
- 2001-02-12 IL IL15048001A patent/IL150480A0/xx active IP Right Grant
- 2001-02-21 EG EG20010167A patent/EG24073A/xx active
- 2001-02-23 CO CO01014634A patent/CO5261585A1/es not_active Application Discontinuation
- 2001-02-23 AR ARP010100844A patent/AR029471A1/es unknown
- 2001-02-23 SV SV2001000321A patent/SV2002000321A/es unknown
- 2001-02-23 MY MYPI20010823A patent/MY124784A/en unknown
- 2001-02-23 PE PE2001000194A patent/PE20011082A1/es not_active Application Discontinuation
- 2001-02-23 TW TW090104119A patent/TWI237024B/zh not_active IP Right Cessation
- 2001-12-02 UA UA2002086886A patent/UA72791C2/uk unknown
2002
- 2002-06-27 IL IL150480A patent/IL150480A/en not_active IP Right Cessation
- 2002-07-01 ZA ZA200205265A patent/ZA200205265B/xx unknown
- 2002-08-21 NO NO20023974A patent/NO323422B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA004684B1 (ru)	2004-06-24
IL150480A0 (en)	2002-12-01
CA2400155C (en)	2009-09-15
JP2003530321A (ja)	2003-10-14
PT1259513E (pt)	2004-02-27
ES2206403T3 (es)	2004-05-16
WO2001062760A3 (en)	2001-12-06
NZ519796A (en)	2003-01-31
IL150480A (en)	2007-12-03
UA72791C2 (uk)	2005-04-15
KR100744917B1 (ko)	2007-08-01
NO20023974L (no)	2002-08-21
PE20011082A1 (es)	2001-10-22
DE60100750T2 (de)	2004-07-29
EA200200905A1 (ru)	2003-02-27
HRP20020701A2 (en)	2003-12-31
MY124784A (en)	2006-07-31
US7138521B2 (en)	2006-11-21
ZA200205265B (en)	2003-11-11
EP1259513B1 (en)	2003-09-10
CZ303772B6 (cs)	2013-05-02
PL356423A1 (en)	2004-06-28
KR20020075449A (ko)	2002-10-04
BR0108604A (pt)	2002-11-19
SI1259513T1 (en)	2003-12-31
SK11862002A3 (sk)	2003-01-09
MXPA02008242A (es)	2002-11-29
NO20023974D0 (no)	2002-08-21
HUP0204232A2 (hu)	2003-04-28
AU777047B2 (en)	2004-09-30
EP1259513A2 (en)	2002-11-27
NO323422B1 (no)	2007-04-30
HK1051856A1 (en)	2003-08-22
ATE249462T1 (de)	2003-09-15
AU3445101A (en)	2001-09-03
CZ20022875A3 (cs)	2003-02-12
TWI237024B (en)	2005-08-01
DE60100750D1 (de)	2003-10-16
CN1183135C (zh)	2005-01-05
HUP0204232A3 (en)	2006-01-30
SK287375B6 (sk)	2010-08-09
US20030216416A1 (en)	2003-11-20
AR029471A1 (es)	2003-07-02
EG24073A (en)	2008-05-11
JP4846158B2 (ja)	2011-12-28
DZ3283A1 (fr)	2001-08-30
SV2002000321A (es)	2002-07-16
CO5261585A1 (es)	2003-03-31
CN1406238A (zh)	2003-03-26
HU229704B1 (en)	2014-05-28
DK1259513T3 (da)	2004-01-12
PL208061B1 (pl)	2011-03-31
WO2001062760A2 (en)	2001-08-30
CA2400155A1 (en)	2001-08-30

Publication	Publication Date	Title
HRP20020701B1 (en)	2011-02-28	A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
EP1578411A4 (en)	2007-05-02	PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3)
WO2001014379A3 (en)	2001-09-07	A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
CA2379560A1 (en)	2001-02-08	Purine derivatives inhibitors of tyrosine protein kinase syk
CY1113322T1 (el)	2016-06-22	3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ
ES2151156T3 (es)	2000-12-16	Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados.
GR3033449T3 (en)	2000-09-29	Piperazine derivatives as 5ht1a antagonists
MY140674A (en)	2010-01-15	New crystalline form of a triazolo(4,5-d)pyrimidine compound
ES2144077T3 (es)	2000-06-01	Formas de administracion que contienen sales solidas de acido r-tioctico con liberacion y biodisponibilidad mejoradas.
MXPA02007819A (es)	2004-09-10	Sales cristalinas del acido 7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil) amino)pirimidin-5-il)-(3r, 5s)-3, 5-dihidroxihept-6-enoico.
JO2371B1 (en)	2006-12-12	4-phenyl-pyridine derivatives
CO4700469A1 (es)	1998-12-29	3-[4-(4(4-cianofenil)-1-piperazinanil)butil]-5]ciannoindol y su proceso de obtencion .
TR200000721T2 (tr)	2000-11-21	Vitronektin reseptör antagonistleri.
EA199700106A1 (ru)	1997-12-30	Замещенные 2-фенилпиридины в качестве гербицидов
PL373247A1 (en)	2005-08-22	Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
PL369502A1 (en)	2005-04-18	Salts of substituted 1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid derivatives
HK1060256A (en)	2004-08-06	Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
TH78405S (th)	2006-07-06	ลวดลายจาน
TH25918S1 (th)	2009-04-30	ลวดลายจาน
UY27271A1 (es)	2003-11-28	Composiciones farmacéuticas
TH18805S1 (th)	2005-07-15	นาฬิกาตั้งโต๊ะ
TH61749S (th)	2004-04-30	นาฬิกาตั้งโต๊ะ
TH18653S1 (th)	2005-06-14	นาฬิกาตั้งโต๊ะ
TH61750S (th)	2004-04-30	นาฬิกาตั้งโต๊ะ
TH23234S1 (th)	2008-02-08	ครอบโค้งสันตะเข้

Legal Events

Date	Code	Title	Description
2003-12-31	A1OB	Publication of a patent application
2004-02-26	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-02-28	B1PR	Patent granted
2018-02-08	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20180208 Year of fee payment: 18
2019-09-18	PBON	Lapse due to non-payment of renewal fee	Effective date: 20190212